X0306 4 2020-08-16 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 1 1 0 0 CEO and President Common Stock 2020-08-16 4 M 0 5129 A 4690854 D Common Stock 2020-08-16 4 F 0 1774 28.53 D 4689080 D Common Stock 2085372 I See footnote Common Stock 927686 I See footnote Restricted Stock Units 2020-08-16 4 M 0 5129 0.00 D Common Stock 5129 76940 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,129 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. /s/ Tara Condon, Attorney-in-Fact 2020-08-18